Novo Nordisk comeback stirs as Wegovy pill wins UK approval
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Novo Nordisk’s Wegovy (semaglutide) pill, marking another regulatory win…
12 Jun 2026
China’s NMPA approves Akeso’s gumokimab for plaque psoriasis
Akeso has received approval from China's National Medical Products Administration (NMPA) for gumokimab (AK111), an anti-Interleukin-17 (IL-17) monoclonal antibody, to treat adults with moderate-to-severe plaque psoriasis. The approval is based…
12 Jun 2026
FDA grants priority review for Roche’s Tecentriq combo sBLA
Roche has received the US Food and Drug Administration (FDA) priority review for its supplemental biologics licence application (sBLA) for adjuvant Tecentriq (atezolizumab) and Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) in…
11 Jun 2026
Drug developers eye sport’s biggest stage as World Cup fever builds
As Mexico prepares to take on South Africa in the opening game of the 2026 FIFA World Cup today (11 June), a handful of pharmaceutical companies are set to contribute…
11 Jun 2026
XtalPi enters $400m partnership for small molecule therapy for GPCR target
XtalPi has entered a strategic partnership valued at more than $400m with an international biopharmaceutical company to develop oral small-molecule therapeutics targeting a G protein-coupled receptor (GPCR). The collaboration follows…
11 Jun 2026
Beren pockets $300m to take Niemann-Pick disease therapy to market
Beren Therapeutics has secured $300m in combined funding to support the potential commercial launch of its infantile-onset Niemann-Pick disease, type C (I-NPC) therapy, adrabetadex. Split into an Eisai-backed equity funding…
11 Jun 2026
EMA validates Bayer’s asundexian application for ischaemic stroke
The European Medicines Agency (EMA) has validated Bayer's marketing authorisation application for asundexian, an oral Factor XIa inhibitor, to prevent ischaemic stroke. EMA has now begun reviewing its use in…